Cyclophilin-D: A Regulator of Mitochondrial Oxidative Phosphorylation
Project Number1I01BX002771-01A2
Contact PI/Project LeaderGAZMURI, RAUL JAIME
Awardee OrganizationEDWARD HINES JR VA HOSPITAL
Description
Abstract Text
Cyclophilin-D (Cyp-D) is a peptidyl prolyl isomerase which catalyzes the cis-trans isomerization of peptidyl
prolyl bonds and thereby regulates conformational changes of target proteins. Cyp-D is the only cyclophilin res-
ident in mitochondria, and until recently it was best known for its effect on the mitochondrial permeability transi-
tion pore. We recently discovered that Cyp-D interacts with two of the three mitochondrial transcription factors
(i.e., TFB1M and TFB2M but not TFAM) and subsequently found that Cyp-D also interacts with the mitochon-
drial RNA polymerase. Genetic silencing of Cyp-D in isolated cells disrupted mitochondrial gene expression re-
sulting in a reduction in mitochondrial O2 consumption (VO2). More recently, working with a constitutive Cyp-D
knock out (Cyp-D KO) mice, we showed also in vivo reductions in VO2 (at rest and exercise). Concomitantly,
the respiratory exchange ratio increased suggesting a metabolic shift favoring utilization of carbohydrates over
fat. Intriguingly, the exercise capacity was increased pointing to an adaptive response whereby O2 utilization
efficiency was increased. Using in silico modeling, we have identified small molecules able to destabilize the
interaction between Cyp-D and TFB2M. Thus, we hypothesize that Cyp-D plays a key role in oxygen me-
tabolism by regulating mitochondrial gene expression and signaling an adaptive increase in oxygen
utilization efficiency. We propose to further this hypothesis based on two specific aims. Specific Aim 1: De-
signed to complete the characterization of the Cyp-D effects on mitochondrial gene expression using cardiac
relevant tissue and examine additional downstream processes – also mediated by Cyp-D – that may impact
cell respiration (structured in 4 Sub Aims). Sub-Aim 1, designed to completely characterize the interactions
among key players of the mitochondrial transcription machinery and assess their dependency on Cyp-D PPI-
ase activity; Sub-Aim 2, designed to confirm that the effects of Cyp-D on mitochondrial gene expression are
HSP2 specific (as suggested by preliminary data) and to assess whether Cyp-D silencing could signal up-
stream and affect the expression of nuclear-encoded proteins of respiratory complexes; Sub-Aim 3, designed
to confirm that Cyp-D silencing reduces mitochondrial encoded subunits of the respiratory chain complexes
and F1FoATP synthase and examine whether Cyp-D overexpression results in the opposite effect; and Sub-
Aim 4, to investigate whether Cyp-D also acts as chaperone aiding in the assembly of respiratory complexes.
Studies under Specific Aim 1 will be conducted in adult mouse primary cardiomyocytes, fibroblasts, and tissues
from Cyp-D KO and wild-type (WT) mice when relevant. Cyp-D will be modulated by using lentiviral vectors
harboring constructs to silence or overexpress Cyp-D and pharmacological inhibition using cyclosporine A
(CsA) and newly identified small molecules. Specific Aim 2: Designed to determine the functional conse-
quences of genetic ablation or pharmacological inhibition of Cyp-D in mice and examine the underlying adap-
tive mechanisms leading to increased O2 utilization efficiency. Cyp-D activity will be reduced by using constitu-
tive and conditional Cyp-D KO mice and by pharmacological inhibition with cyclosporine A and small molecules
able to selectively destabilize the interaction between Cyp-D and TFB2M. With constitutive Cyp-D KO mice, we
will assess whether the findings in cell systems after acute Cyp-D ablation also occur in vivo and examine the
adaptive responses leading to increased O2 utilization efficiency. With conditional Cyp-D KO mice, we will as-
sess the immediate effects of Cyp-D ablation and whether an adaptive response occurs, subsequently examin-
ing whether similar effects can be elicited through pharmacological inhibition. Myocardial energy effects along
with functional myocardial effects will be assessed using 31P magnetic resonance spectroscopy and magnetic
resonance imaging. Understanding the underlying mechanisms of increase O2 utilization efficiency may have
important implications for human physiology and disease and plan to also examine effects in acute conditions
of reduced O2 availability using models of cardiac arrest and hemorrhagic shock.
Public Health Relevance Statement
Mitochondria are considered the power houses of all cells. They extract energy from nutrients and store it in
molecules of ATP representing the “energy currency” of the body essential to maintain a healthy life. The pro-
cess by which ATP is produced is known as oxidative phosphorylation and requires the seamless work of mul-
tiple structures inside mitochondria. We found evidence that a mitochondrial protein known as cyclophilin-D
(Cyp-D) regulates the production of ATP. We propose to fully characterize the role of Cyp-D in regulating the
production of ATP and to test the effects of changing it levels in cells and in mice. Our proposal is highly rele-
vant to Veterans because mitochondrial abnormalities occur in conditions such as aging, cancer, neurodegen-
erative disease, vascular disease, ischemia reperfusion, heart failure, and response to stressors. Careful re-
duction of Cyp-D levels might permit organs to save energy while increasing their resistance to various illness-
es and have an overall impact on the various illnesses that afflict Veterans.
No Sub Projects information available for 1I01BX002771-01A2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1I01BX002771-01A2
Patents
No Patents information available for 1I01BX002771-01A2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1I01BX002771-01A2
Clinical Studies
No Clinical Studies information available for 1I01BX002771-01A2
News and More
Related News Releases
No news release information available for 1I01BX002771-01A2
History
No Historical information available for 1I01BX002771-01A2
Similar Projects
No Similar Projects information available for 1I01BX002771-01A2